Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 5/20 | 0.42 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | APP | P05067 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 2/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12821346 | 0.91 | NAAA (0.34) | NAAAAPPFFAR4 | |
| SCHEMBL13586129 | 0.90 | NAAA (0.40) | NAAAKDM1AAPPFAAHACACB | |
| SCHEMBL12823254 | 0.89 | NAAA (0.33) | NAAAAPPACACB | |
| SCHEMBL12736785 | 0.88 | NAAA (0.43) | NAAAKDM1AFAAHFPR2FFAR4 | |
| SCHEMBL12736786 | 0.88 | NAAA (0.45) | NAAAKDM1AFPR2FFAR4RET | |
| SCHEMBL14765857 | 0.88 | NAAA (0.45) | NAAAKDM1AFPR2FFAR4 | |
| SCHEMBL12821322 | 0.88 | KDM1A (0.37) | NAAAKDM1AAPPFAAHACACB | |
| SCHEMBL12716349 | 0.87 | KDM1A (0.41) | NAAAKDM1AAPPFAAHACACB | |
| SCHEMBL12736778 | 0.87 | NAAA (0.44) | NAAAKDM1AFPR2FFAR4RET | |
| SCHEMBL10303312 | 0.87 | KDM1A (0.42) | NAAAKDM1AFAAHACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
| WO-2009150966-A1 | TETRACYCLIC LIQUID CRYSTALLINE COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | チッソ株式会社 (JP) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | NAAA 3997/4885KDM1A 937/4885APP 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.